stockrowApimeds Pharmaceuticals US, Inc. (APUS) vs PainReform Ltd. (PRFX)
- Apimeds Pharmaceuticals US, Inc. APUS 2.62 −4.03%
- PainReform Ltd. PRFX 0.84 +10.53%
Apimeds Pharmaceuticals US, Inc. and PainReform Ltd. are both Drug Manufacturers Specialty & Generic companies. Apimeds Pharmaceuticals US, Inc. is the larger, with a market value of $4.1M against $2.3M — 1.8× the size. Across the 10 metrics below, PainReform Ltd. leads on 7 and Apimeds Pharmaceuticals US, Inc. on 3.
Valuation
| Metric | APUS | PRFX | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| P/E | n/m | n/m | 20.55 |
| P/S | n/m | n/m | 2.08 |
| P/B | 0.04 | 0.00 | 1.79 |
| Price to free cash flow | n/m | n/m | 16.29 |
| EV/EBITDA | n/m | 0.97 | 12.22 |
| EV/Sales | n/m | n/m | 2.87 |
| Earnings yield | (1,394.72%) | (156,798.70%) | (15.94%) |
| Free cash flow yield | (295.94%) | (101,853.01%) | 0.00% |
Profitability
| Metric | APUS | PRFX | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | — | 0.00% | 53.51% |
| Operating margin | 0.00% | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% | (2.45%) |
| Free cash flow margin | 0.00% | 0.00% | 0.00% |
| Return on equity | (100.13%) | 0.00% | (0.80%) |
| Return on assets | (84.20%) | 0.00% | (1.67%) |
| Return on invested capital | (15.96%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack